- Home
- CATX vs YMAB Comparison
CATX vs YMAB Comparison
Compare CATX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- YMAB
- Stock Information
- Founded
- CATX 1983
- YMAB 2015
- Country
- CATX United States
- YMAB United States
- Employees
- CATX N/A
- YMAB N/A
- Industry
- CATX Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- YMAB Health Care
- Exchange
- CATX Nasdaq
- YMAB Nasdaq
- Market Cap
- CATX 239.0M
- YMAB 192.4M
- IPO Year
- CATX N/A
- YMAB 2018
- Fundamental
- Price
- CATX $3.67
- YMAB $4.53
- Analyst Decision
- CATX Strong Buy
- YMAB Buy
- Analyst Count
- CATX 11
- YMAB 10
- Target Price
- CATX $12.90
- YMAB $17.00
- AVG Volume (30 Days)
- CATX 954.5K
- YMAB 163.6K
- Earning Date
- CATX 08-13-2025
- YMAB 08-11-2025
- Dividend Yield
- CATX N/A
- YMAB N/A
- EPS Growth
- CATX N/A
- YMAB N/A
- EPS
- CATX N/A
- YMAB N/A
- Revenue
- CATX $1,471,000.00
- YMAB $88,658,000.00
- Revenue This Year
- CATX N/A
- YMAB N/A
- Revenue Next Year
- CATX $11.99
- YMAB $15.15
- P/E Ratio
- CATX N/A
- YMAB N/A
- Revenue Growth
- CATX N/A
- YMAB 4.92
- 52 Week Low
- CATX $1.60
- YMAB $3.55
- 52 Week High
- CATX $16.55
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- CATX 44.88
- YMAB 48.47
- Support Level
- CATX $3.88
- YMAB $4.64
- Resistance Level
- CATX $4.28
- YMAB $5.18
- Average True Range (ATR)
- CATX 0.27
- YMAB 0.27
- MACD
- CATX -0.08
- YMAB 0.02
- Stochastic Oscillator
- CATX 2.32
- YMAB 33.67
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.